logo-loader

e-Therapeutics files more patents for its gene silencing technology

Last updated: 07:33 16 Jan 2024 GMT, First published: 10:40 07 Dec 2020 GMT

Snapshot

  • e-therapeutics 'actively exploring' potential partnerships as AI approach yields results
  • e-Therapeutics using Open AI technology in drug discovery
  • e-Therapeutics working to capitalise on AI "blindside"
scientist in a lab

About the company

e-Therapeutics PLC is integrating computational power and biology to accelerate the discovery of life-transforming RNAi medicines.

The company has developed and validated a powerful computational approach to drug discovery, leveraging our industry-leading expertise in network biology to fully capture and interrogate human disease complexity.

e-Therapeutics' multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support.

How it is doing

16 Jan 2024

e-Therapeutics PLC said it has made "remarkable progress" in developing RNAi drug targets using artificial intelligence (AI) - and doing so against a tough financial backdrop for the sector and the wider economy.

Leading the update were the advancements in several major drug candidates. ETX-407, a promising treatment for dry age-related macular degeneration, stands out as a potential game-changer in patient-friendly therapeutic options, the company said.

ETX-312, meanwhile, showed "exceptional results" in the diet-induced obesity model of NASH/MASH1. Additionally, the company has completed preclinical studies for ETX-148 in haemophilia treatment and ETX-291 for cardiometabolic disease while making continued progress on ETX-258 for an undisclosed indication.

"Both ETX-407 and ETX-312 have the potential to be highly differentiated, first-on-target medicines in diseases with high unmet need and we are excited to be progressing these assets towards the clinic," said chief executive Ali Mortazavi.

02 Nov 2023

e-Therapeutics PLC has sealed a partnership with Arcturis Data that will use the pair's technology and insights to help develop treatments for metabolic dysfunction, including nonalcoholic steatohepatitis (NASH), a type of liver disease.

This collaboration will bring together Arcturis' Real-World Evidence, a platform filled with clinically rich, high-quality real-world data, and e-therapeutics' computational biology platform, HepNet.

26 Oct 2023

During the 2023 interim period, AIM-listed biotech company e-Therapeutics PLC continued to grow and advance its GalOmic RNAi therapeutics against target genes discovered using the group’s HepNet computational platform.

Through HepNet, e-therapeutics also generated positive proof-of-concept data for ETX-291 in cardiometabolic disease and ETX-148 in haemophilia.

Insight: e-Therapeutics using Open AI technology in drug discovery

04 May 2023

e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF) has long been at the vanguard of computational drug discovery.

Now, chief executive Ali Mortazavi has signalled the company’s intent to use Open AI’s GPT large language model (LLM) to further automate the quest to find new drug targets, notably in the area of gene silencing.

What management says

04 May 2023

e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF) CEO Ali Mortazavi speaks to Thomas Warner following the release of the computational biology and chemistry company's full year results for 2022.

Mortazavi says that it was a "tricky year for the biotechnology sector as a whole" but that eTherapeutics has shown "remarkable resilience."

He goes on to highlight the opportunity being presented to the company by the advent of large language models (LLMs) and GPT-4, saying that he's never before seen a technology "blindside the world" to such an extent.

e-Therapeutics present at the Proactive One2One Investor Forum - October 26th

Ali Mortazavi, CEO of e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF), addressed the challenges of traditional drug discovery, emphasising its high risk, extensive timeline, and considerable cost at the Proactive One2One Investor Forum. Underlining the inefficiencies of this model, Mortazavi posed...

on 1/11/23